Covered recipient · General Payments record
JESSICA FAHRBACH O'NEILL
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2024
$2,920.36
- Reported across 145 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $298.42 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Abbott Laboratories | $71.76 | 4 |
| ABBVIE INC. | $49.76 | 3 |
| BOSTON SCIENTIFIC CORPORATION | $45.65 | 1 |
| Exact Sciences Corporation | $36.93 | 2 |
| Amgen Inc. | $29.96 | 2 |
| Medtronic, Inc. | $18.88 | 1 |
| Astellas Pharma US Inc | $17.03 | 1 |
| Novo Nordisk AS | $15.02 | 1 |
| Merck Sharp & Dohme Corporation | $13.43 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $20.13 | 02/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125067453 | CMS |
| Abbott Laboratories | $19.98 | 06/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125067455 | CMS |
| Abbott Laboratories | $15.89 | 09/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125067459 | CMS |
| Abbott Laboratories | $15.76 | 12/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1125067457 | CMS |
| ABBVIE INC. | $21.33 | 01/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103223743 | CMS |
| ABBVIE INC. | $14.75 | 02/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103223745 | CMS |
| ABBVIE INC. | $13.68 | 04/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103223747 | CMS |
| Amgen Inc. | $14.98 | 04/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117190529 | CMS |
| Amgen Inc. | $14.98 | 07/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117190531 | CMS |
| Astellas Pharma US Inc | $17.03 | 02/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139310682 | CMS |
| Boston Scientific Corporation | $45.65 | 10/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1092357804 | CMS |
| Exact Sciences Corporation | $17.78 | 09/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114410861 | CMS |
| Exact Sciences Corporation | $19.15 | 12/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114410866 | CMS |
| Medtronic, Inc. | $18.88 | 02/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1119319580 | CMS |
| Merck Sharp & Dohme LLC | $13.43 | 10/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141810538 | CMS |
| Novo Nordisk Inc | $15.02 | 02/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096715473 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.